Department of Medicine, Angliss Hospital, Melbourne, Victoria, Australia.
Department of Critical Care Medicine, Royal Hobart Hospital, Hobart, Tasmania, Australia.
Intern Med J. 2017 Jan;47(1):109-111. doi: 10.1111/imj.13307.
Methylenedioxypyrovalerone (MDPV) is a synthetic, cathinone-derivative, central nervous system stimulant taken to produce a cocaine- or methamphetamine-like high. Physical manifestations include tachycardia, hypertension, arrhythmias, hyperthermia, sweating, rhabdomyolysis, hyperkalaemia, disseminated intravascular coagulation, oliguria and seizures. We report a patient who presented with severe metabolic acidosis, multi-organ dysfunction, rhabdomyolysis, hyperkalaemia and seizures. This case highlights that even though a urine drug screen for routine psychostimulant drugs is negative, clinicians need to be vigilant about the adverse effects of MDPV as a possible cause of multi-organ dysfunction. Substances such as this can only be detected by special tests, such as gas/liquid chromatography mass spectrometry. This is the first reported case of MDPV toxicity successfully treated in Australia to the best of our knowledge.
3,4-亚甲二氧基吡咯戊酮（MDPV）是一种合成的、苯丙胺衍生物的中枢神经系统兴奋剂，被用来产生类似可卡因或甲基苯丙胺的兴奋感。身体表现包括心动过速、高血压、心律失常、体温过高、出汗、横纹肌溶解、高钾血症、弥散性血管内凝血、少尿和癫痫发作。我们报告了一例患者，该患者表现为严重的代谢性酸中毒、多器官功能障碍、横纹肌溶解症、高钾血症和癫痫发作。本病例强调，即使常规精神兴奋剂尿液药物筛查呈阴性，临床医生也需要警惕 MDPV 作为多器官功能障碍的可能病因的不良反应。此类物质只能通过特殊测试（如气相/液相色谱-质谱法）来检测。据我们所知，这是在澳大利亚首次成功治疗 MDPV 毒性的报告病例。
